Incidence and Determinants of COVID-19 in Patients Seeking Treatment for Substance Use Disorder: A Patient-Based Linkage Study.


Journal

European addiction research
ISSN: 1421-9891
Titre abrégé: Eur Addict Res
Pays: Switzerland
ID NLM: 9502920

Informations de publication

Date de publication:
2023
Historique:
received: 01 07 2022
accepted: 05 12 2022
medline: 4 10 2023
pubmed: 17 8 2023
entrez: 16 8 2023
Statut: ppublish

Résumé

People with substance use disorder (SUD) may be at increased risk of COVID-19 infection. However, there is little evidence regarding the incidence of and determinants associated with infection in this group. The aims of the study were to determine the cumulative incidence of COVID-19 among people who sought treatment for heroin, cocaine, cannabis, and alcohol use disorder in Catalonia; to identify sociodemographic, substance, and clinical determinants associated with COVID-19 infection among SUD patients; and to compare the cumulative incidence of COVID-19 infection in the population with SUD with that of the general population. A patient-based retrospective observational study was conducted. The study population comprised people who sought treatment for heroin, cocaine, cannabis, or alcohol use disorder in Catalonia in 2018 and 2019. We analysed cumulative incidence of COVID-19 (confirmed by PCR test) from 25 February to 31 December 2020. Additionally, we used a log-link binomial generalized linear model for COVID-19 infection, using the substance as the exposition, adjusting for sociodemographic and clinical variables. Of the 23,092 individuals who sought treatment for SUD, 38.15% were considered suspected cases of COVID-19, and 2.60% (95% CI = 2.41-2.82) were confirmed positive for COVID-19 by PCR test during the study period. Those who sought treatment for alcohol use (cumulative incidence of COVID-19 of 3% [95% CI = 2.70-3.34]) had a higher risk ratio than, those who sought treatment for heroin use (cumulative incidence of 1.94% [95% CI = 1.47-2.56]). Being born outside of Spain, living in an institutionalized residence, having HIV, and being in a high morbidity group were associated with higher risk of COVID-19 infection. Meanwhile, the cumulative incidence of COVID-19 in the general population, according to public COVID-19 test data, was 3.86% (95% CI = 3.85-3.87). This study did not find higher cumulative incidence of COVID-19 infection among people with SUD in Catalonia in 2020, despite the clinical vulnerability of this population and their social disadvantage. However, differences were seen in the cumulative incidence of COVID-19 according to the substance for which treatment was sought. For example, those with alcohol dependence had a higher rate than those dependent on heroin. Further studies are needed to determine the factors contributing to these differences.

Identifiants

pubmed: 37586329
pii: 000528647
doi: 10.1159/000528647
pmc: PMC10614235
doi:

Substances chimiques

Heroin 70D95007SX
Cocaine I5Y540LHVR

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

333-343

Informations de copyright

© 2023 S. Karger AG, Basel.

Références

Lancet HIV. 2021 Nov;8(11):e701-e710
pubmed: 34655549
Rev Esp Salud Publica. 2005 Jun 01;79:391-401
pubmed: 28272387
Lancet Public Health. 2020 Apr;5(4):e188-e189
pubmed: 32197116
Lancet Public Health. 2020 Apr;5(4):e186-e187
pubmed: 32171054
Scand J Public Health. 2022 Feb;50(1):52-60
pubmed: 33983088
Psychiatr Serv. 2021 May 1;72(5):578-581
pubmed: 33138712
Dan Med J. 2020 Nov 20;67(12):
pubmed: 33269697
Med Clin (Barc). 2005 Apr 16;124(14):525-31
pubmed: 15847748
JAMA. 2020 May 19;323(19):1891-1892
pubmed: 32293639
N Engl J Med. 2020 Apr 2;382(14):1289-1290
pubmed: 32242351
J Public Health (Oxf). 2021 Sep 22;43(3):462-465
pubmed: 33367823
Addict Behav. 2015 Jun;45:281-6
pubmed: 25747796
BMC Public Health. 2021 Jun 16;21(1):1150
pubmed: 34130683
Addiction. 2017 Jun;112(6):968-1001
pubmed: 28220587
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Public Health (Oxf). 2021 Apr 12;43(1):9-12
pubmed: 33103716
Am J Public Health. 2010 Aug;100(8):1454-61
pubmed: 20558789
Psychiatry Res. 2021 Jun;300:113915
pubmed: 33836472
Biom J. 2006 Feb;48(1):5-22
pubmed: 16544809
BMJ Open. 2016 Apr 15;6(4):e010301
pubmed: 27084274
Mol Psychiatry. 2021 Jan;26(1):30-39
pubmed: 32929211
FEMS Immunol Med Microbiol. 2006 Aug;47(3):330-42
pubmed: 16872369
MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(50-51):1445-1452
pubmed: 28033313
J Addict Med. 2020 Sep/Oct;14(5):e261-e263
pubmed: 32530889
Clin Microbiol Rev. 2003 Apr;16(2):209-19
pubmed: 12692094
Euro Surveill. 2020 Dec;25(50):
pubmed: 33334400
MMWR Morb Mortal Wkly Rep. 2020 May 01;69(17):521-522
pubmed: 32352957
Pharmaceuticals (Basel). 2020 Jul 18;13(7):
pubmed: 32708495
J Epidemiol Community Health. 2019 Feb;73(2):97-99
pubmed: 30389719
J Epidemiol Community Health. 2022 Apr;76(4):350-353
pubmed: 34583961
Nat Commun. 2021 Feb 3;12(1):777
pubmed: 33536436
Ann Intern Med. 2020 Jul 7;173(1):61-62
pubmed: 32240293
J Addict Med. 2017 Jan/Feb;11(1):3-9
pubmed: 27610582
JAMA. 2020 Jun 2;323(21):2191-2192
pubmed: 32338732
Mol Psychiatry. 2021 Sep;26(9):4568-4569
pubmed: 33589741

Auteurs

Irene Lana-Lander (I)

Public Health Agency of Catalonia, Department of Health, Government of Catalonia, Programme on Substance Abuse, Barcelona, Spain.

Regina Muñoz-Galán (R)

Public Health Agency of Catalonia, Department of Health, Government of Catalonia, Programme on Substance Abuse, Barcelona, Spain.

Jorge Palacio-Vieira (J)

Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia (CEEISCAT), Badalona, Spain.

Xavier Majo-Roca (X)

Public Health Agency of Catalonia, Department of Health, Government of Catalonia, Programme on Substance Abuse, Barcelona, Spain.

Elisenda Martínez-Carbonell (E)

Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Barcelona, Spain.

Robert Muga (R)

Servei de Medicina Interna, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain.

Joan Colom (J)

Public Health Agency of Catalonia, Department of Health, Government of Catalonia, Programme on Substance Abuse, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH